CSL Limited is a global biotechnology leader, driven by its promise to save and improve lives using the latest technologies. Since its inception as Commonwealth Serum Laboratories in 1916, CSL has been at the forefront of medical innovation, initially serving Australia's health needs during a time of global conflict. The company's relentless pursuit of groundbreaking solutions has led to significant advancements in treating rare and serious diseases, as well as preventing widespread illnesses like influenza. Through its diverse businesses—CSL Behring, CSL Seqirus, and CSL Vifor—CSL has established a formidable presence in over 100 countries, developing and delivering a dynamic portfolio of lifesaving medicines. This includes critical treatments for conditions such as hemophilia and immune deficiencies, a comprehensive range of influenza vaccines, and innovative therapies for iron deficiency and nephrology.
At the core of CSL's success is a profound commitment to research and development. The company invests heavily in exploring new frontiers in biotechnology, including plasma-derived therapies, recombinant protein technology, cell and gene therapy, and mRNA vaccine platforms. This dedication to innovation is embodied by its more than 2,000 R&D employees and significant financial investment in advancing its product pipeline. CSL's operational excellence extends to its extensive plasma collection network, CSL Plasma, which is one of the largest in the world, ensuring a reliable supply of this critical raw material. By consistently pushing the boundaries of science and technology, CSL is not just responding to current health challenges but is actively shaping the future of medicine, striving to provide patients worldwide with the opportunity to live fuller lives. The company's enduring values and patient-focused culture continue to propel its mission to protect public health and deliver on its promise of a healthier tomorrow.
ES and US only
United States
Australia